CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Restructuring and Related Cost, Cost Incurred to Date
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Restructuring and Related Cost, Cost Incurred to Date of $95.00 million as of 2024-09-28, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2024-11-06
- 2024-09-28: Restructuring and Related Cost, Cost Incurred to Date $95.00M.
- 2024-06-29: Restructuring and Related Cost, Cost Incurred to Date $65.00M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2024-09-28 | $95.00M 10-Q · filed 2024-11-06 |
| 2024-06-29 | $65.00M 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |